ATEZOLIZUMAB

atezolizumab 840 mg/14 mL injection, 14 mL vial

ATEZOLIZUMAB (12097Q)

atezolizumab 840 mg/14 mL injection, 14 mL vial
12097Q
Body System:
Manner of administration:Injection
Public
Chemotherapy Items for Public Hospital use
Authority Required (STREAMLINED)

Restriction  10257

Indication: Stage IV (metastatic) non-small cell lung cancer (NSCLC)
Treatment phase: Continuing first-line treatment of metastatic disease, as monotherapy, where concomitant bevacizumab has ceased due to intolerance - 4 weekly treatment regimen
Quantities & Cost
Max amount # of repeats DPMA Max safety net General Patient Charge
Max amount: 1680 mg # of repeats: 5 DPMA: $9,537.53 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Tecentriq
(atezolizumab 840 mg/14 mL injection, 14 mL vial)